Abstract: The present invention relates to a novel peptide or a partial sequence thereof for enhancing expression efficiency of a target protein, and a fusion protein comprising the same. The novel peptide according to the present invention can enhance expression efficiency of a target protein, and furthermore, the peptide can also be applied to a solubility-enhancing fusion protein in order to enhance solubility of the target protein, so that solubility as well as expression efficiency of the target protein is enhanced, which allows such a peptide to be usefully used for production of a recombinant target protein.

Abstract: The present invention relates to a fusion protein for enhancing expression efficiency of a target protein. More specifically, the present invention relates to a glutamyl-prolyl-tRNA synthetase from human (hEPRS) WHEP domain (including WHEP domains TRS-1, TRS-2, and TRS-3 which locate at middle sites of the EPRS protein, and linkers connecting the three domains therethrough). When used as a fusion protein for expressing a target protein in E. coli, the hEPRS WHEP domain according to the present invention enhanced water solubility of the target protein.

Abstract: The present invention relates to a nanoperforator having a lipid-bilayer nanodisc and a membrane-structured protein surrounding the nanodisc and to a pharmaceutical composition having the nanoperforator as an active ingredient for preventing or treating viral infectious diseases. The use of the lipid-bilayer nanoperforator provided in the present invention can lead to the safe prevention or treatment of a disease caused by viral infection regardless of whether the virus is a variant or not, and thus the present invention can be widely used for the safe and effective treatment of viral infectious diseases.

Abstract: The present invention relates to an anti-inflammatory composition, and more particularly to an anti-inflammatory composition containing, as an active ingredient, a compound represented by Formula 1 or a salt thereof, wherein the anti-inflammatory composition may inhibit inflammatory response even at an early stage by inhibiting the interaction between CD14 and LPS and blocking the expression of CD14 and the expression of TNF? and IL-1?, which are the key factors in inflammatory response, and may also regulate the expression of important factors, such as CCL2 (MCP-1), CCL7 (MCP-3), CXCL2, CHOP and NOX1, which are involved in inflammatory response.

Abstract: The present invention relates to a novel peptide or a partial sequence thereof for enhancing expression efficiency of a target protein, and a fusion protein comprising the same. The novel peptide according to the present invention can enhance expression efficiency of a target protein, and furthermore, the peptide can also be applied to a solubility-enhancing fusion protein in order to enhance solubility of the target protein, so that solubility as well as expression efficiency of the target protein is enhanced, which allows such a peptide to be usefully used for production of a recombinant target protein.

Abstract: Provided are a marker for detecting a highly pathogenic influenza virus including a protein mutant prepared by substituting the amino acids 68 and 69 of a PB1-F2 protein, a composition for detecting a highly pathogenic virus including an agent for measuring the protein mutant, and a detection kit including the same, a method for detecting a highly pathogenic virus including measuring the protein mutant, an antiviral composition against influenza A virus including an inhibitor of binding between a PB1-F2 protein in which the amino acids 68 and 69 are substituted and DDX3, and a method for screening an antiviral substance against influenza A virus.

Abstract: Disclosed is a universal influenza vaccine composition and corresponding methods comprising at least one attenuated live-attenuated influenza vaccine. The vaccine composition can exhibit a cross-protective effect against a wide range of influenza viruses and can ensure a strong protection efficacy, a wide range of protection, and safety. In addition, a vaccination method of heterologous live vaccines of the present invention induces various immunological effects so that cross-immunogenicity and cross-protective ability are remarkably increased, and thus is expected to be usefully utilized as a universal influenza prevention method. A person who has a basal immunity through infection with an influenza virus or vaccination with an influenza vaccine can be regarded as being in a state where primary vaccination has already been performed, single vaccination with a live vaccine induces an enhanced cross-immune response, and thus it is possible to expect a wide range of protective effects against various viruses.

Abstract: The present invention relates to an anti-inflammatory composition, and more particularly to an anti-inflammatory composition containing, as an active ingredient, a compound represented by Formula 1 or a salt thereof, wherein the anti-inflammatory composition may inhibit inflammatory response even at an early stage by inhibiting the interaction between CD14 and LPS and blocking the expression of CD14 and the expression of TNF? and IL-1?, which are the key factors in inflammatory response, and may also regulate the expression of important factors, such as CCL2 (MCP-1), CCL7 (MCP-3), CXCL2, CHOP and NOX1, which are involved in inflammatory response.

Abstract: Provided are a marker for detecting a highly pathogenic influenza virus including a protein mutant prepared by substituting the amino acids 68 and 69 of a PB1-F2 protein, a composition for detecting a highly pathogenic virus including an agent for measuring the protein mutant, and a detection kit including the same, a method for detecting a highly pathogenic virus including measuring the protein mutant, an antiviral composition against influenza A virus including an inhibitor of binding between a PB1-F2 protein in which the amino acids 68 and 69 are substituted and DDX3, and a method for screening an antiviral substance against influenza A virus.

Abstract: Disclosed is a universal influenza vaccine composition and corresponding methods comprising at least one attenuated live-attenuated influenza vaccine. The vaccine composition can exhibit a cross-protective effect against a wide range of influenza viruses and can ensure a strong protection efficacy, a wide range of protection, and safety. In addition, a vaccination method of heterologous live vaccines of the present invention induces various immunological effects so that cross-immunogenicity and cross-protective ability are remarkably increased, and thus is expected to be usefully utilized as a universal influenza prevention method. A person who has a basal immunity through infection with an influenza virus or vaccination with an influenza vaccine can be regarded as being in a state where primary vaccination has already been performed, single vaccination with a live vaccine induces an enhanced cross-immune response, and thus it is possible to expect a wide range of protective effects against various viruses.

Abstract: The present invention relates to a nanoperforator having a lipid-bilayer nanodisc and a membrane-structured protein surrounding the nanodisc and to a pharmaceutical composition having the nanoperforator as an active ingredient for preventing or treating viral infectious diseases. The use of the lipid-bilayer nanoperforator provided in the present invention can lead to the safe prevention or treatment of a disease caused by viral infection regardless of whether the virus is a variant or not, and thus the present invention can be widely used for the safe and effective treatment of viral infectious diseases.

Abstract: The present invention relates to a vaccine composition containing a virus inactivated by a green tea extract, and a preparation method therefor. According to the present invention, when a virus is treated with a green tea extract, there are simultaneous effects of virus inactivation and excellent immunogenicity maintenance, and thus an inactivated vaccine can be prepared by mixing the green tea extract of the present invention and a virus with a proliferative capacity, and infectious diseases caused by the corresponding virus can be effectively prevented since an immune reaction to the corresponding virus is induced when a vaccine composition prepared by the preparation method of the present invention is administered to a subject.

Abstract: Disclosed is an attenuation method of an influenza virus, that is, a reassortant virus and a preparation method thereof. The disclosed reassortant virus has, in a ratio of 6:2, genes encoding a recombinant non-toxic protein and a wild type non-toxic protein, and genes encoding toxic proteins, HA (hemagglutinin) and NA (neuraminidase), of an influenza virus, the recombinant non-toxic protein consisting of a substituted caspase recognition sequence without a change of a protein size within the wild type non-toxic protein of the influenza virus. The disclosed attenuated influenza virus shows a high attenuation without a reduction of productivity in a fertilized egg. Accordingly, the method can be used as an economically efficient live vaccine preparation method which has both safety and efficiency and can use a fertilized egg as a production system.

Abstract: A system and method of detecting separator lines in a web page may include determining coordinates of visible web elements on a web page, generating an edge image of the web page based on the coordinates of the web elements, filtering edges belonging to non-separator line elements within the edge image, detecting horizontal lines within the edge image, detecting vertical lines within the edge image, and filtering short lines within the edge image. A system for detecting separator lines in a web page may include a memory device, and a processor communicatively coupled to the memory, in which the processor determines coordinates of visible web elements on a web page, generates an edge image of the web page based on the coordinates of the web elements, filters edges belonging to non-separator line elements within the edge image, detects horizontal lines within the edge image, detects vertical lines within the edge image, and filters short lines within the edge image.

Abstract: Disclosed is an attenuation method of an influenza virus, that is, a reassortant virus and a preparation method thereof. The disclosed reassortant virus has, in a ratio of 6:2, genes encoding a recombinant non-toxic protein and a wild type non-toxic protein, and genes encoding toxic proteins, HA (hemagglutinin) and NA (neuraminidase), of an influenza virus, the recombinant non-toxic protein consisting of a substituted caspase recognition sequence without a change of a protein size within the wild type non-toxic protein of the influenza virus. The disclosed attenuated influenza virus shows a high attenuation without a reduction of productivity in a fertilized egg. Accordingly, the method can be used as an economically efficient live vaccine preparation method which has both safety and efficiency and can use a fertilized egg as a production system.

Abstract: Disclosed is a method for improving folding efficiency and solubility of a target protein linked to a RNA-binding protein by using RNA molecule as a molecular chaperone, wherein the RNA molecule interacts with the RNA-binding protein. More particularly, the present invention discloses method for improving folding efficiency and solubility of a target protein by transformation of a host cell with a expression vector comprising a polynucleotide encoding the target protein linked to an RNA-binding protein; culturing the transformed host cell in an appropriate culture medium under the condition that an RNA molecule either resident inside the host cell or provided by cotransformation of the host cell with polynucleotide encoding the RNA molecule interacts with the RNA-binding protein; and purifying the soluble protein from host cell lysate. The method of the present invention is very useful for production of soluble proteins for therapeutic, prophylactic and diagnostic applications.

Abstract: The present invention relates to an isolated attenuated influenza virus strain and a live vaccine comprising the same. The isolated attenuated influenza virus strain is prepared by cold-adaptation of a mother strain which carries 6 internal genomes of A/PR/8/34(H1N1) and two surface antigens HA and NA of A/Aichi/2/68(H3N2). The attenuated influenza virus strain and the live vaccine of the present invention are useful for prevention of seasonal influenza episodes and sudden outbreak of influenza pandemics of predicted or unknown identity, since they have safety, efficacy, high production yield, immediate protection against variety of influenza subtypes and prolonged protection against specific influenza subtype.

Abstract: The present invention relates to an isolated attenuated influenza virus strain and a live vaccine comprising the same. The isolated attenuated influenza virus strain is prepared by cold-adaptation of a mother strain which carries 6 internal genomes of A/PR/8/34(H1N1) and two surface antigens HA and NA of A/Aichi/2/68(H3N2). The attenuated influenza virus strain and the live vaccine of the present invention are useful for prevention of seasonal influenza episodes and sudden outbreak of influenza pandemics of predicted or unknown identity, since they have safety, efficacy, high production yield, immediate protection against variety of influenza subtypes and prolonged protection against specific influenza subtype.

Abstract: The present invention relates to novel expression vectors which can produce foreign proteins as soluble forms by using lysyl-tRNA synthetase and a process for preparing foreign proteins by using the expression vectors. Particularly, the present invention relates to the expression vectors which can provide foreign proteins as fused and soluble forms by exploiting the structure and expression pattern of lysyl-tRNA synthetase and the processes for preparing foreign proteins in E. coli effectively, which can be utilized industrially to produce active proteins in mass.

Abstract: The present invention relates to novel expression vectors which can produce foreign proteins as soluble forms by using lysyl-tRNA synthetase and a process for preparing foreign proteins by using the expression vectors. Particularly, the present invention relates to the expression vectors which can provide foreign proteins as fused and soluble forms by exploiting the structure and expression pattern of lysyl-tRNA synthetase and the processes for preparing foreign proteins in E. coli effectively, which can be utilized industrially to produce active proteins in mass.